The short version of analytical methods fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-03 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
==== 2021: Torn Achilles tendon ==== McCormick did not participate in spring football during his recovery in 2021, though he was cleared to return to practice in July of that year. He participated in the 2021 Oregon Ducks football season opener against the Fresno State Bulldogs, seeing action on special teams. He also played and was named the starter during the Ducks' game against the Ohio State Buckeyes, though he exited the game during the second quarter after suffering a torn Achilles tendon in his right foot, a season-ending injury.
March 12: Law expanding the civil capacity of professional unions; married women may join and participate (including in administration and leadership) without their husband's permission. July 31: Law criminalizing incitement to abortion and anti-contraceptive propaganda. August 12: Decree enacting the Peace Treaty of November 27, 1919, which created the League of Nations (SDN) and established principles such as the prohibition of child labor, restrictions on youth labor for both sexes, and "equal pay for equal work"; women may be technical advisors within the SDN on certain topics. 1921
Biocatalyzed kinetic resolution is utilized extensively in the purification of racemic mixtures of synthetic amino acids. Many popular amino acid synthesis routes, such as the Strecker Synthesis, result in a mixture of R and S enantiomers. This mixture can be purified by (I) acylating the amine using an anhydride and then (II) selectively deacylating only the L enantiomer using hog kidney acylase. These enzymes are typically extremely selective for one enantiomer leading to very large differences in rate, allowing for selective deacylation. Finally the two products are now separable by classical techniques, such as chromatography.
Sources: en.wikipedia.org
== In France == Raymond arrived in Europe in 1922 and settled in Paris in 1927. He nonetheless retained links with the newly formed republic of Turkey, and prepared sketches for Turkey's projected participation in the 1925 International Exposition of Decorative Arts in Paris.
Shanimol Osman (born 30 May 1966) is an Indian politician from Kerala. She currently serves as the Deputy Speaker of the Kerala Legislative Assembly. She represents Aroor constituency in the Kerala Legislative Assembly since 21 May 2026. Shanimol is a member of the Indian National Congress.
IgE was simultaneously discovered in 1966–67 by two independent groups: Ishizaka's team at the Children's Asthma Research Institute and Hospital in Denver, USA, and by Gunnar Johansson and Hans Bennich in Uppsala, Sweden. Their joint paper was published in April 1969.
As late as the 1960s, the element was also referred to simply as emanation. The first synthesized compound of radon, radon fluoride, was obtained in 1962. Even today, the word radon may refer to either the element or its isotope 222Rn, with thoron remaining in use as a short name for 220Rn to stem this ambiguity. The name actinon for 219Rn is rarely encountered today, probably due to the short half-life of that isotope. The danger of high exposure to radon in mines, where exposures can reach 1,000,000 Bq/m3, has long been known. In 1530, Paracelsus described a wasting disease of miners, the mala metallorum, and Georg Agricola recommended ventilation in mines to avoid this mountain sickness (Bergsucht). In 1879, this condition was identified as lung cancer by Harting and Hesse in their investigation of miners from Schneeberg, Germany. The first major studies with radon and health occurred in the context of uranium mining in the Joachimsthal region of Bohemia. In the US, studies and mitigation only followed decades of health effects on uranium miners of the Southwestern US employed during the early Cold War; standards were not implemented until 1971. In the early 20th century in the US, gold contaminated with the radon daughter 210Pb entered the precious metal supply chain of that country's jewelry industry. Gold brachytherapy seeds that had held 222Rn were illicitly or unknowingly sold and melted down. The presence of radon in indoor air was documented as early as 1950.
Sources: en.wikipedia.org
=== Fire fighting === Surfactants are used in firefighting (to make "wet water" that more quickly soaks into flammable materials) and pipelines (liquid drag reducing agents). "Wet water" provides the advantage of allowing the extinguishing water to penetrate burning materials such as wood or fabric more effectively, thereby enhancing its cooling capacity. Additionally, extinguishing water mixed with surface-active agents can be sprayed over greater distances at the same pumping capacity due to their flow-improving properties. Special foaming agents (Aqueous Film Forming Foam, AFFF) for combating liquid fires contain perfluorinated surfactants that form a gas-tight liquid film between the burning material and the foam. This simultaneously imparts superior sliding properties to the foam blanket, thereby enabling the effective extinguishment of larger liquid fires.
It is generally incorrect to state that Cauchy stress is a function of merely a strain tensor, as such a model lacks crucial information about material rotation needed to produce correct results for an anisotropic medium subjected to vertical extension in comparison to the same extension applied horizontally and then subjected to a 90-degree rotation; both these deformations have the same spatial strain tensors yet must produce different values of the Cauchy stress tensor. Even though the stress in a Cauchy-elastic material depends only on the state of deformation, the work done by stresses might depend on the path of deformation. Therefore, Cauchy elasticity includes non-conservative "non-hyperelastic" models (in which work of deformation is path dependent) as well as conservative "hyperelastic material" models (for which stress can be derived from a scalar "elastic potential" function).
=== 2010–2012: SODMG, Mad Decent, various mixtapes === Beginning in 2011, Riff Raff began to be managed by OG Ron C (of Swishahouse fame) and moved to Los Angeles. Riff Raff then started releasing more music videos that furthered the artist's internet fame. Those include songs such as "Jose Canseco", and "Marc Jacobs". Then in mid-2011, Riff Raff signed to Soulja Boy's label S.O.D. Money Gang Inc. Riff Raff joined Soulja Boy's SODMG label before they met in person; no paperwork was ever signed. However, Riff Raff still wore the imprint's chain, got its logo tattooed, and again adjusted his stage name, this time to Riff Raff SODMG. They would remain affiliated for around a year, but the label did not push or pay Riff Raff, which would result in him leaving the label. Soulja Boy publicly called Riff Raff a "cokehead" following their split. Some time before the official split Riff Raff affiliated with producers such as Diplo and Harry Fraud, as well as with Queens rapper Action Bronson. The music video he released for his collaboration with Fraud and Bronson, "Bird on a Wire", hit the one million plays-mark in roughly two months. "Bird on a Wire" was listed as the 27th best song of 2012 by Complex Music. In early 2012 he would release music videos for the songs, "Larry Bird", "Time" and the Chief Keef collaboration "Cuz My Gear", among others. In April 2012, Riff Raff also announced a collaborative album with Diplo tentatively titled Jody Highroller with guests Skrillex, Usher, Soulja Boy, Gucci Mane, Mystikal and Rusko.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.